SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Apple Restores Telegram to App Store After Content Policy Violation 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
MENLO PARK, Calif., March 19, 2018 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:30 PM EDT.
A live audio webcast of Corium’s presentation may be accessed here or by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumintl.com. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
[email protected]
(201) 923-2049
Source: Corium
